Annual balance sheet for Bioxytran, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.072 | 0.295 | 0.026 | 0.005 | 0.51 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.072 | 0.295 | 0.026 | 0.005 | 0.513 |
| Net Intangible Assets | |||||
| Total Assets | 0.119 | 0.371 | 0.139 | 0.139 | 0.659 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.28 | 3.66 | 3.24 | 1.93 | 3.25 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Liabilities | 2.88 | 3.07 | 2.56 | 1.93 | 3.25 |
| Redeemable Preferred Stock | |||||
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -2.76 | -2.7 | -2.42 | -1.79 | -2.59 |
| Total Liabilities & Shareholders' Equity | 0.119 | 0.371 | 0.139 | 0.139 | 0.659 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |